Pharma BD Deal Intelligence
PTC acquires a BLA-stage Fabry gene therapy out of Sangamo's bankruptcy auction
Full analysis, sources & comparables →PTC Therapeutics was selected as the winning bidder in Sangamo Therapeutics' competitive bankruptcy asset auction to acquire ST-920 (isaralgagene civaparvovec), a BLA-stage one-time AAV gene therapy for Fabry disease that delivers a functional copy of the GLA gene. PTC will pay USD 111 million in cash at closing plus up to USD 100 million in milestones - USD 80 million on FDA accelerated approval and USD 20 million on full or traditional FDA approval - for headline consideration of up to USD 211 million. A rolling BLA submission for accelerated approval is expected to complete in Q4 2026. The auction was part of a broader Sangamo process yielding USD 163.55 million in aggregate cash at closing across successful bidders and is subject to bankruptcy court approval.
Fabry disease is a rare X-linked lysosomal storage disorder caused by GLA gene mutations leading to alpha-galactosidase A deficiency, with progressive renal, cardiac and cerebrovascular complications. Standard care is lifelong enzyme replacement or chaperone therapy; ST-920 is designed as a one-time AAV gene therapy delivering a functional GLA gene.
PTC Therapeutics was selected as winning bidder for ST-920 at $111M cash at closing plus up to $100M in approval milestones. Buying at BLA stage out of a distressed process compresses the usual development risk window - a rolling BLA for accelerated approval is expected to complete in Q4 2026 - but the sale remains subject to bankruptcy court approval.
PTC acquires a BLA-stage Fabry gene therapy out of Sangamo's bankruptcy auction
| Deal | Year | Value | Outcome |
|---|---|---|---|
| PTC Therapeutics Inc. / Sangamo Therapeutics, Inc. (this deal) | 2026 | $211M | 70 |
| PTC Therapeutics Inc. / Censa Pharmaceuticals | 2020 | $268M | — |
| Arcturus Therapeutics, Inc. / CSL Seqirus (CSL Limited) | 2026 | $28M | 100 |
| Genentech, Inc. (Roche Group) / Duality Biologics (Suzhou) Co. Ltd. | 2026 | $1.0B | 100 |
| Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd. | 2026 | $2.3B | 100 |
| Servier Pharmaceuticals LLC / Day One Biopharmaceuticals Inc. | 2026 | $2.5B | 75 |
| Servier / Edgewise Therapeutics, Inc. | 2026 | $2.6B | 75 |
← Browse all deals · How we score deals
More: 2026 deals